Dr. Lal Path Labs Ltd.
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomi… Read more
Market Cap & Net Worth: Dr. Lal Path Labs Ltd. (LALPATHLAB)
Dr. Lal Path Labs Ltd. (NSE:LALPATHLAB) has a market capitalization of $2.61 Billion (₹226.27 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #6642 globally and #237 in its home market, demonstrating a 1.19% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dr. Lal Path Labs Ltd.'s stock price ₹1355.10 by its total outstanding shares 166973474 (166.97 Million).
Dr. Lal Path Labs Ltd. Market Cap History: 2015 to 2026
Dr. Lal Path Labs Ltd.'s market capitalization history from 2015 to 2026. Data shows growth from $1.47 Billion to $2.61 Billion (5.53% CAGR).
Index Memberships
Dr. Lal Path Labs Ltd. is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY SMALLCAP 100
NIFSMCP100
|
$104.59 Billion | 1.13% | #28 of 100 |
|
NIFTY 500
NIFTY500
|
$1.33 Trillion | 0.09% | #221 of 500 |
|
NIFTY HEALTHCARE
NIFTYHEALTHCARE
|
$72.50 Billion | 1.63% | #15 of 20 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$535.62 Billion | 0.22% | #139 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.39 Trillion | 0.09% | #217 of 750 |
|
NIFTY SMALLCAP 250
NISM250
|
$188.43 Billion | 0.63% | #40 of 250 |
Weight: Dr. Lal Path Labs Ltd.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Dr. Lal Path Labs Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dr. Lal Path Labs Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.12x
Dr. Lal Path Labs Ltd.'s market cap is 0.12 times its annual revenue
0.68x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.59x
Dr. Lal Path Labs Ltd.'s market cap is 0.59 times its annual earnings
359.02x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.96 Billion | $7.91 Billion | $1.32 Billion | 0.25x | 1.48x |
| 2017 | $1.62 Billion | $9.12 Billion | $1.55 Billion | 0.18x | 1.05x |
| 2018 | $1.68 Billion | $10.57 Billion | $1.71 Billion | 0.16x | 0.99x |
| 2019 | $2.78 Billion | $12.03 Billion | $1.99 Billion | 0.23x | 1.40x |
| 2020 | $4.32 Billion | $13.30 Billion | $2.26 Billion | 0.32x | 1.91x |
| 2021 | $7.21 Billion | $15.81 Billion | $2.92 Billion | 0.46x | 2.47x |
| 2022 | $4.29 Billion | $20.87 Billion | $3.45 Billion | 0.21x | 1.24x |
| 2023 | $4.92 Billion | $20.17 Billion | $2.39 Billion | 0.24x | 2.06x |
| 2024 | $5.78 Billion | $22.27 Billion | $3.58 Billion | 0.26x | 1.62x |
| 2025 | $2.86 Billion | $24.61 Billion | $4.87 Billion | 0.12x | 0.59x |
Competitor Companies of LALPATHLAB by Market Capitalization
Companies near Dr. Lal Path Labs Ltd. in the global market cap rankings as of March 18, 2026.
Key companies related to Dr. Lal Path Labs Ltd. by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #91 globally with a market cap of $176.18 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #154 globally with a market cap of $120.38 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.34 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #512 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #91 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.18 Billion | $470.00 |
| #154 | Danaher Corporation | NYSE:DHR | $120.38 Billion | $191.39 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.34 Billion | $586.37 |
| #512 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Dr. Lal Path Labs Ltd. Historical Marketcap From 2015 to 2026
Between 2015 and today, Dr. Lal Path Labs Ltd.'s market cap moved from $1.47 Billion to $ 2.61 Billion, with a yearly change of 5.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹2.61 Billion | -8.60% |
| 2025 | ₹2.86 Billion | -50.59% |
| 2024 | ₹5.78 Billion | +17.66% |
| 2023 | ₹4.92 Billion | +14.62% |
| 2022 | ₹4.29 Billion | -40.54% |
| 2021 | ₹7.21 Billion | +66.87% |
| 2020 | ₹4.32 Billion | +55.28% |
| 2019 | ₹2.78 Billion | +65.26% |
| 2018 | ₹1.68 Billion | +3.94% |
| 2017 | ₹1.62 Billion | -17.30% |
| 2016 | ₹1.96 Billion | +33.46% |
| 2015 | ₹1.47 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Dr. Lal Path Labs Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.61 Billion USD |
| MoneyControl | $2.61 Billion USD |
| MarketWatch | $2.61 Billion USD |
| marketcap.company | $2.61 Billion USD |
| Reuters | $2.61 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.